Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved

Masato Yoneda; Takashi Kobayashi; Naohiro Wada; Tomohiro Otani; Asako Nogami; Michihiro Iwaki; Atsushi Nakajima

doi:10.21037/hbsn-23-342

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved

Hepatobiliary Surg Nutr. 2023 Oct 1;12(5):759-762. doi: 10.21037/hbsn-23-342. Epub 2023 Sep 4.

Authors

Masato Yoneda¹, Takashi Kobayashi¹, Naohiro Wada¹, Tomohiro Otani¹, Asako Nogami¹, Michihiro Iwaki¹, Atsushi Nakajima¹

Affiliation

¹ Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama, Japan.

No abstract available

Keywords: Nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); obesity; selective non-acid farnesoid X receptor agonists (selective non-acid FXR agonists); tropifexor.

Publication types

Editorial
Comment